Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 12:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,055 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: No Therapy 6 Weeks Clear all
Terminated Phase 2 Interventional Results available

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

NCT04738292
View directory record Official record
Conditions
ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer
Interventions
Onapristone, Fulvestrant
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 13, 2026, 12:45 PM EDT
Completed Phase 1 Interventional Results available

Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

NCT03568058
View directory record Official record
Conditions
Advanced Cancer
Interventions
Personalized Vaccine, Pembrolizumab
Drug
Lead sponsor
Aaron Miller
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 13, 2026, 12:45 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Her2-BATS and Pembrolizumab in Metastatic Breast Cancer

NCT03272334
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
HER2 BATs with Pembrolizumab
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 13, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)

NCT02573493
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck, Cancer of the Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck
Interventions
nab-Paclitaxel, Cisplatin, Cetuximab, Intensity-Modulated Radiation Therapy
Drug · Biological · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Westwood, Kansas • St Louis, Missouri • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 13, 2026, 12:45 PM EDT
Completed Not applicable Interventional

Bioimpedance Spectroscopy Versus Tape Measure in Prevention of Lymphedema (PREVENT)

NCT02167659
View directory record Official record
Conditions
Lymphedema
Interventions
23-32 mmHg compression sleeve with gauntlet
Device
Lead sponsor
ImpediMed Limited
Industry
Eligibility
18 Years and older
Enrollment
1,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
9
States / cities
Jacksonville, Florida • Kansas City, Kansas • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 13, 2026, 12:45 PM EDT
Recruiting Phase 3 Interventional

PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation

NCT05699174
View directory record Official record
Conditions
Infections, Infected Wound, Nonunion of Fracture, Injury Leg, Amputation, Internal Fixation; Complications, Infection or Inflammation, Fracture, Lower Extremity Fracture, Antibiotic Side Effect
Interventions
Standard of Care PO (oral) antibiotics, Standard of Care Intravenous (IV) antibiotics
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Minneapolis, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 13, 2026, 12:45 PM EDT
Completed Phase 1 Interventional

Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors

NCT00003710
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, mitomycin C
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Oct 13, 2026, 12:45 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A

NCT03020160
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Sacramento, California • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 13, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme

NCT01209442
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Bevacizumab, Temozolomide, RT (Radiation Therapy)
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 13, 2026, 12:45 PM EDT
Withdrawn Phase 2 Interventional

QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

NCT03365661
View directory record Official record
Conditions
High-Risk Acute Myeloid Leukemia, Treatment-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
ALT-803
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 9, 2018 · Synced Oct 13, 2026, 12:45 PM EDT
Terminated Phase 2 Interventional Results available

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

NCT04272242
View directory record Official record
Conditions
HIV Infection, LTBI
Interventions
Dolutegravir (DTG), Isoniazid (INH), Rifapentine (RPT), Antiretroviral Therapy (ART), Pyridoxine (Vitamin B6)
Drug · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
San Francisco, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 13, 2026, 12:45 PM EDT
Completed Phase 1 Interventional

HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA

NCT02379520
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma, Human Papillomavirus Positive Cervical Carcinoma, Human Papillomavirus Positive Anal Carcinoma, Human Papillomavirus Positive Vulvar Carcinoma, Human Papillomavirus Positive Penile Carcinoma
Interventions
HPV Specific T Cells, Cytoxan, Fludarabine, Nivolumab
Genetic · Drug · Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 12:45 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy

NCT06993597
View directory record Official record
Conditions
Glaucoma
Interventions
Prostaglandin Analogue -Containing IOP-Lowering Therapy, Beta Blocker, Brillouin Microscopy
Drug · Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 13, 2026, 12:45 PM EDT
Active, not recruiting No phase listed Observational

Improving Infant Hydrocephalus Outcomes in Uganda

NCT03650101
View directory record Official record
Conditions
Hydrocephalus
Interventions
ETV/CPC
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Day to 180 Days
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 13, 2026, 12:45 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effectiveness and Implementation of Text Messaging to Improve HIV Testing in Adolescents

NCT06096519
View directory record Official record
Conditions
HIV
Interventions
Information, motivation, behavioral skills treatment arm, Information only control arm
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
13 Years to 19 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 13, 2026, 12:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

NCT02010567
View directory record Official record
Conditions
Rectal Cancer
Interventions
CRLX101, Capecitabine, Radiotherapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
6
States / cities
Denver, Colorado • Indianapolis, Indiana • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 13, 2026, 12:45 PM EDT
Not yet recruiting Phase 1 Interventional

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

NCT07217496
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Urothelial Cancer, Bladder Cancer
Interventions
Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 13, 2026, 12:45 PM EDT
Not listed No phase listed Observational

Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain

NCT05812703
View directory record Official record
Conditions
Chronic Pain, Sedentary Time
Interventions
Cognitive Behavioral Therapy, Acceptance and Commitment Therapy (ACT), Moderate to high Intensity Group Exercise
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 13, 2026, 12:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Gender and Culturally Specific Approach to Reduce NAFLD in Mexican-American Men

NCT04186260
View directory record Official record
Conditions
NAFLD
Interventions
NAFLD-specific weight loss intervention, Wait-list control
Behavioral · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 64 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 13, 2026, 12:45 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Physical Activity in Promoting Smoking Cessation in African Americans

NCT01915810
View directory record Official record
Conditions
Current Smoker, Healthy Subject
Interventions
Exercise Intervention, Laboratory Biomarker Analysis, Nicotine Patch, Questionnaire Administration, Tobacco Cessation Counseling
Behavioral · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 13, 2026, 12:45 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Platelet Rich Plasma Injections In Young And Old Human Subjects

NCT06451120
View directory record Official record
Conditions
Osteoarthritis, Articular Cartilage, Musculoskeletal Disorders
Interventions
Platelet-Rich Plasma (PRP) Injections, Centrifuge, Control saline injection
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 13, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

NCT00536978
View directory record Official record
Conditions
Lymphoma, Leukemia
Interventions
ARA-C, BCNU, Campath-1H, Cyclophosphamide, Etoposide, Fludarabine, Melphalan, Rituximab, Allogeneic Stem Cell Transplantation, Total body radiation (TBI), Methotrexate, Tacrolimus, Adback NK or T Cell
Drug · Other · Radiation + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 13, 2026, 12:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cognitive Effects of Treatment of Interictal Discharges

NCT00916149
View directory record Official record
Conditions
Epilepsy
Interventions
levetiracetam, Lamotrigine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 13, 2026, 12:45 PM EDT
Completed Not applicable Interventional Results available

A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans

NCT03331978
View directory record Official record
Conditions
HIV/AIDS
Interventions
Rise - Treatment Education
Behavioral
Lead sponsor
RAND
Other
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 13, 2026, 12:45 PM EDT